Thunderbolt licenses Astellas B-cell program | Chemical & Engineering News
Volume 94 Issue 22 | p. 15 | Concentrates
Issue Date: May 30, 2016

Thunderbolt licenses Astellas B-cell program

Department: Business
Keywords: start-ups, drug discovery, b-cell disorders, lupus

Thunderbolt Pharma has become the first company created by Vitesse Biologics, a drug development collaboration formed by Baxalta, Mayo Clinic, and Velocity Pharmaceutical Development. Thunderbolt has acquired a BAFF/APRIL dual antagonist program from Astellas Pharma. With the three Vitesse partners contributing financially, Thunderbolt will develop the dual antagonists for B-cell-mediated disorders including systemic lupus erythematosus. Baxalta, Mayo Clinic, Velocity, and Astellas are all shareholders in Thunderbolt.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment